Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.36 |
| ▸ | CDYL2 | Q8N8U2 | 4/20 | 0.35 |
| ▸ | CDYL | Q9Y232 | 4/20 | 0.35 |
| ▸ | CBX7 | O95931 | 3/20 | 0.35 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 2/20 | 0.35 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4858969 | 0.87 | CALCRL (0.40) | CALCRLCYP3A4L3MBTL3L3MBTL1CDYL2 | |
| SCHEMBL5394689 | 0.85 | CALCRL (0.41) | CALCRLCYP3A4L3MBTL3L3MBTL1CDYL2 | |
| SCHEMBL6804176 | 0.84 | PDE3B (0.37) | CALCRLL3MBTL3L3MBTL1MBTD1ALDH1A1 | |
| SCHEMBL4861348 | 0.80 | CALCRL (0.39) | CALCRLCYP3A4L3MBTL3L3MBTL1CDYL2 | |
| SCHEMBL3598608 | 0.80 | PARP1 (0.35) | CALCRLCYP3A4ALDH1A1 | |
| SCHEMBL4593019 | 0.80 | CALCRL (0.39) | CALCRLCYP3A4L3MBTL3L3MBTL1CDYL2 | |
| SCHEMBL4860518 | 0.80 | CALCRL (0.39) | CALCRLCYP3A4L3MBTL3L3MBTL1CDYL2 | |
| SCHEMBL4855630 | 0.80 | CALCRL (0.39) | CALCRLCYP3A4L3MBTL3L3MBTL1CDYL2 | |
| SCHEMBL4860278 | 0.80 | CALCRL (0.39) | CALCRLCYP3A4L3MBTL3L3MBTL1CDYL2 | |
| SCHEMBL4852142 | 0.79 | CYP3A4 (0.42) | CALCRLCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539766-B1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | claimed |
| EP-1539766-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2005-06-15 | — | — | EP | claimed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
| US-20040063735-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | claimed |
| WO-2003104236-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-18 | — | — | WO | claimed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| US-20040063735-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063735-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | CALCRL 1/4885CYP3A4 3269/4885L3MBTL3 4841/4885 |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | CALCRL 1/4885CYP3A4 3269/4885L3MBTL3 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.